Publication date: Feb 21, 2019 This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 ... Read more

Publication date: Feb 21, 2019 Melanoma tumors that have spread to the brain are equipped to thwart immunotherapies and targeted therapies that succeed against tumors growing in other sites. Researchers ... Read more

Publication date: Feb 21, 2019 Although melanoma – a type of skin cancer – is expected to claim 7,230 lives this year, according to the American Cancer Society, new hope ... Read more

Publication date: Feb 21, 2019 High 1-year overall survival (OS) rate was associated with stereotactic radiosurgery (SRS) followed by either immunotherapy or targeted therapy, according to results of a retrospective ... Read more

Publication date: Feb 21, 2019 Drug combinations used for the treatment of non-small-cell lung cancer (NSCLC) and melanoma aren’t as effective as they could be. Oncologists haven’t had the right ... Read more

Publication date: Feb 21, 2019 The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, applauds the U.S. Food & Drug Administration (FDA) approval of Merck’s pembrolizumab ... Read more

Publication date: Feb 20, 2019 Credit: Kimmel Cancer Center Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and the Johns Hopkins University School of Medicine report two ... Read more

Publication date: Feb 20, 2019 The FDA has approved the PD-1 inhibitor pembrolizumab (Keytruda) for the adjuvant treatment of patients with high-risk stage III melanoma with lymph node involvement following ... Read more

Publication date: Feb 20, 2019 Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and the Johns Hopkins University School of Medicine report two new forms of an ... Read more

Publication date: Feb 20, 2019 The Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) – an immunotherapy agent – for the treatment of patients with resected, high-risk, stage 3 melanoma. ... Read more